Literature DB >> 23549434

Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections.

Anteneh M Feyissa1, Parbhdeep Singh, Robert G Smith.   

Abstract

Two patients with known human immunodeficiency virus (HIV) infections and receiving antiretroviral treatment developed neuromyelitis optica (Devic's disease). One patient tested positive for serum aquaporin-4 immunoglobulin G antibodies. Both patients were treated with high dose pulsed intravenous methylprednisolone followed by standard sessions of plasma exchange both at the onset attack and during disease relapses. For maintenance therapy, one patient received rituximab infusions and the second patient received mycophenolate mofetil orally. Despite treatment, both patients are currently wheelchair-bound due to severe paraparesis. Neuromyelitis optica can occur in the course of HIV infection and poses an ongoing therapeutic challenge.

Entities:  

Keywords:  Aquaporin-4 antibody; Devic’s disease; HIV; NMO; neuromyelitis optica; plasma exchange

Mesh:

Year:  2013        PMID: 23549434     DOI: 10.1177/1352458513483891

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  4 in total

1.  Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.

Authors:  Joshua Chalkley; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  Multiple sclerosis and HIV-1 infection: case report of a HIV controller.

Authors:  Jerome H Chin
Journal:  J Neurovirol       Date:  2015-03-24       Impact factor: 2.643

Review 3.  Herpes zoster preceding neuromyelitis optica spectrum disorder: casual or causal relationship? A systematic literature review.

Authors:  Emanuela Claudia Turco; Erica Curti; Francesco Pisani; Franco Granella
Journal:  J Neurovirol       Date:  2022-04-24       Impact factor: 2.643

4.  The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa.

Authors:  Ahmed I Bhigjee; Anandan A Moodley; Izanne Roos; Cait-Lynn Wells; Pratistadevi Ramdial; Monika Esser
Journal:  South Afr J HIV Med       Date:  2017-01-31       Impact factor: 2.744

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.